Earnings History Data for Exicure, Inc. (XCUR) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Exicure, Inc.

Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.

Release Date	Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
25-03-2022	AH	XCUR	Exicure, Inc.	32.45	-0.15	-0.17	-0.15	Exicure GAAP EPS of -$0.72 [3/25/2022 4:26 PM]	0.1972	-0.06 (-24.15%)	0.20	0.01 (2.84%)	0.14 - 2.25	13,025,614	8,210,000	43,282
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress [Mar-25-22 04:15PM]
19-11-2021	PM	XCUR	Exicure, Inc.	68.46	-0.27	-0.16	-0.10	Exicure EPS misses by $0.17, misses on revenue [11/19/2021 7:04 AM]	0.4594	-0.20 (-30.18%)	0.61	-0.05 (-7.29%)	0.46 - 2.83	3,231,684	470,000	106,466
Exicure EPS misses by $0.17, misses on revenue [11/19/2021 7:04 AM] Exicure Shareholder Alert [Nov-17-21 06:00PM] INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm [Nov-17-21 02:35PM] EQUITY ALERT: Rosen Law Firm Encourages Exicure, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation XCUR [Nov-17-21 09:06AM] INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm [Nov-18-21 09:45AM] INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Exicure, Inc. (XCUR) on Behalf of Investors [Nov-19-21 07:12PM]
12-08-2021	PM	XCUR	Exicure, Inc.	111.75	-0.16	-0.15	-0.05	Exicure EPS misses by $0.02, misses on revenue [8/12/2021 7:51 AM]	1.22	0.04 (3.39%)	1.16	-0.02 (-1.69%)	1.13 - 2.83	1,204,784	13,090,000	24,820
Exicure EPS misses by $0.02, misses on revenue [8/12/2021 7:51 AM] Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress [Aug-12-21 07:00AM]
12-05-2021	AH	XCUR	Exicure, Inc.	153.00	-0.14	-0.13	0.00	Exicure EPS misses by $0.02, misses on revenue [5/12/2021 4:48 PM]	1.54	-0.14 (-8.04%)	1.66	-0.02 (-1.19%)	1.38 - 3.30	634,897	300,000	5,417
Exicure EPS misses by $0.02, misses on revenue [5/12/2021 4:48 PM] Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress [May-12-21 04:05PM] Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO) [May-13-21 05:24PM]
11-03-2021	PM	XCUR	Exicure, Inc.	184.00	-0.15	-0.10	0.00	Exicure EPS misses by $0.02, misses on revenue [3/11/2021 9:22 AM]	2.49	0.55 (28.35%)	2.00	0.06 (3.09%)	0.96 - 3.30	2,353,367	644,133	5,789
Exicure EPS misses by $0.02, misses on revenue [3/11/2021 9:22 AM] Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress [Mar-11-21 08:45AM] Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University [Mar-11-21 10:03AM]
12-11-2020	PM	XCUR	Exicure, Inc.	158.76	-0.10	-0.09	-0.09	Exicure EPS misses by $0.01, beats on revenue [11/12/2020 7:16 AM]	1.76	-0.18 (-9.28%)	1.98	0.04 (2.06%)	0.96 - 3.84	206,619	139,399	6,428

12-08-2020	PM	XCUR	Exicure, Inc.	202.19	-0.05	-0.09	-0.12	Exicure EPS beats by $0.04, beats on revenue [8/12/2020 7:08 AM]	2.32	0.09 (4.15%)	2.26	-0.04 (-1.74%)	0.96 - 3.84	63,239	137,994	331